Mallinckrodt has received FDA approval for StrataGraft. The drug is intended to treat adults with thermal burns containing intact dermal elements for which surgical intervention is indicated.

Mallinckrodt voluntarily initiated Chapter 11 proceedings in the U.S. Bankruptcy Court to change its capital structure. The company expects to reduce its total debt by approximately $1.3 billion by restructuring its obligations under the procedure. Mallinckrodt and all its subsidiaries continue to operate and supply customers and patients with products as us...

Mallinckrodt incurred a GAAP loss of $983.3 million in the 6 months of 2020 against a profit of $161.7 million in the previous year. Revenue halved to $0.832 bln compared to $1.614 bln a year earlier.

Чистый убыток Mallinckrodt по GAAP за 2019 г. составил $0,996 млрд., что на 72,4% ниже по сравнению с $3,607 млрд. в предыдущем году. Выручка сократилась на 1,6% до $3,162 млрд. против $3,215 млрд. годом ранее.